These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20962614)

  • 1. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial.
    Boué F; Reynes J; Rouzioux C; Emilie D; Souala F; Tubiana R; Goujard C; Lancar R; Costagliola D
    AIDS; 2011 Jan; 25(1):115-8. PubMed ID: 20962614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.
    Maggiolo F; Airoldi M; Callegaro A; Martinelli C; Dolara A; Bini T; Gregis G; Quinzan G; Ripamonti D; Ravasio V; Suter F
    AIDS; 2009 Apr; 23(7):799-807. PubMed ID: 19114869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
    Pai NP; Lawrence J; Reingold AL; Tulsky JP
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.
    Kaufmann GR; Elzi L; Weber R; Furrer H; Giulieri S; Vernazza P; Bernasconi E; Hirschel B; Battegay M;
    AIDS; 2011 Feb; 25(4):441-51. PubMed ID: 21206265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
    Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.
    Goujard C; Emilie D; Roussillon C; Godot V; Rouzioux C; Venet A; Colin C; Pialoux G; Girard PM; Boilet V; Chaix ML; Galanaud P; Chene G;
    AIDS; 2012 Sep; 26(15):1895-905. PubMed ID: 22842994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
    J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Laboratory testing including CD4 T-cell count and determination of viral load to evaluate the impact of first line antiretroviral treatment at 6 months in adults in Benin].
    Ogouyemi-Hounto A; Zannou D; Metodakou D; Lafia B; Gomez V; Akinocho E
    Med Trop (Mars); 2010 Feb; 70(1):100. PubMed ID: 20337131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.
    Florence E; García F; Plana M; Fumero E; Castro P; Lopez A; Cruceta A; Gil C; Arnedo M; Miró JM; Pumarola T; Gallart T; Gatell JM
    Clin Infect Dis; 2004 Aug; 39(4):569-74. PubMed ID: 15356824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting differential responses to structured treatment interruptions during HAART.
    Bajaria SH; Webb G; Kirschner DE
    Bull Math Biol; 2004 Sep; 66(5):1093-118. PubMed ID: 15294419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.